SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network
Silke van Koningsbruggen‐Rietschel, Fiona Dunlevy, Veerle Bulteel, D.G. Downey, Lieven Dupont
Abstract
<b>Rare disease patients may suffer delayed access to new drugs as SARS-CoV-2 is disrupting clinical trials. This survey demonstrates that the European Cystic Fibrosis Clinical Trials Network is ideally placed to track and address such disruption.</b>https://bit.ly/3hCw5dq
Topics & Concepts
Clinical trialDiseaseCystic fibrosisMedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PathologyInternal medicineInfectious disease (medical specialty)Cystic Fibrosis Research AdvancesGenomics and Rare Diseases